Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities

Marketable Securities

3 Months Ended

Mar. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Marketable securities consisted of the following as of March 31, 2024:


March 31, 2024	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	7,397,809	$	—	$	(1,800	)	$	7,396,009
Total	$	7,397,809	$	—	$	(1,800	)	$	7,396,009


December 31, 2023	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	4,085,996	$	877	$	—	$	4,086,873
Total	$	4,085,996	$	877	$	—	$	4,086,873

As of March 31, 2024, the Company held twenty one U.S. Treasury debt securities that were in an unrealized loss position totaling $1,800. As of December 31, 2023, the Company held three U.S. Treasury debt securities that were in an unrealized gain position totaling $877. All U.S. Treasury obligations were due to mature in less than one year for the period and year ended March 31, 2024 and December 31, 2023, respectively.

The Company received proceeds of $5.1 million from maturities of marketable securities for the period ended March 31, 2024. The Company received proceeds of $41.1 million from maturities of marketable securities for the year ended December 31, 2023. The Company did not realize any gains or losses from maturities of marketable securities for the period ended March 31, 2024 or the year ended December 31, 2023.